MedDataX Logo

Safety of an Infant Formula With Hydrolysed Protein in Term Infants

NCT ID: NCT04736082

Last Updated: 2021-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-16

Study Completion Date

2021-10-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multi-centre, randomised, double-blind, parallel-group, controlled, prospective, non-inferiority intervention clinical trial is performed to assess the safety and suitability of an infant formula manufactured from extensively hydrolysed protein by showing normal growth of healthy term infants during the first 120 days of life with an optional follow up until 180 days of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since many years the use of infant formulae manufactured from hydrolysed proteins are recommended for infants at risk for developing allergies if they cannot be exclusively breast-fed. Although the use of such formulae manufactured from hydrolysed protein is legally authorized according to the respective legal framework since many years (currently: Directive 2006/141/EC), the safety of each hydrolysed protein has to be substantiated by additional clinical data according to new legal requirements (Del. Regulation (EU) 2016/127). This study is intended to generate clinical safety data: demonstrating adequate growth of infants fed a formula manufactured from hydrolysed protein in comparison to infants fed a formula manufactured from intact protein. As formula manufactured from hydrolyzed proteins is known to have beneficial effects on gastrointestinal comfort, it is also fed to infants not at risk for developing allergies. Therefore, this study additionally investigates the impact of hydrolysed protein on gastrointestinal tolerance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Safety Growth Weight Gain Infant Formula Infants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group: Infant Formula with hydrolyzed protein

Infants will receive the following infant formula: Infant formula manufactured from extensively hydrolyzed proteins and containing pre- and probiotics.

Group Type EXPERIMENTAL

Intervention Group: Infant Formula with hydrolyzed protein

Intervention Type OTHER

Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).

Control Group: Infant Formula with intact protein

Infants will receive the following infant formula: Infant formula manufactured from intact proteins and containing pre- and probiotics.

Group Type ACTIVE_COMPARATOR

Control Group: Infant Formula with intact protein

Intervention Type OTHER

Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).

Breast Fed Group

Exclusively breast milk

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention Group: Infant Formula with hydrolyzed protein

Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).

Intervention Type OTHER

Control Group: Infant Formula with intact protein

Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female term infants until 25 days of age from singleton pregnancies
* Gestational age ≥37+0 weeks until 41+6 weeks
* Birth weight between ≥3rd and ≤97th percentile per gestational age
* Infants whose parent(s) / legally authorized representative(s) have reached the legal age of consent
* Infants whose parent(s) / legally authorized representative(s) are capable of and willing to comply with the protocol and have signed the informed consent form in accordance with legal requirements
* Infant formula group

* Infants of mothers, who could not breastfeed their healthy newborn babies for reasons not related to this study, or who decided despite the advice on the benefits of breastfeeding to start exclusive formula-feeding within the first 25 days of age of their infant.
* Parent(s) / legally authorized representative(s) confirm their intention to feed their infant the investigational product as the only source of nutrition from 26 days of age onward through the duration of the main study (until 120 days of age), and agree that no other infant formula, drinks (water, tea, juice,…) or complementary foods will be introduced until the infant reaches the age of 120 days.
* Breastfeeding reference group

* Infants of mothers, who decided to exclusively breastfeed their infant until at least 120 days of age
* Parent(s) / legally authorized representative(s) confirm their intention to breastfeed their infant as the only source of nutrition, from 26 days of age onward throughout the duration of the main study (until 120 days of age), and agree that no other infant formula, liquids (water, tea, juice,…) or complementary foods will be introduced until the infant reaches the age of 120 days.

Exclusion Criteria

* Infants whose biological parents or full siblings have a history of doctor's diagnosed atopic diseases (atopic dermatitis, hay fever, allergic asthma or rhinitis) and have been in medical treatment prior to or at enrolment visit
* Intensive care prior to or at enrolment visit
* Severe acquired or congenital illness, or chromosomal anomalies (if known) in infants that are expected to interfere with normal feed or growth
* Hypo- or hypertrophy \<3rd or \>97th percentile of birth weight per gestational age
* Infants under (ongoing) antibiotic treatment before or at enrolment visit longer than three days (72 hours)
* Infants requiring infant formula intake other than those specified in the protocol
* Feeding difficulties or infant formula intolerance
* Disease of parents that may have an impact on study conduct or that may have an influence on infant growth and feeding behaviour based on the investigator's opinion
* Recreational drug or alcohol intake by the mother during the last two trimesters of pregnancy
* Infants born to mothers with medical conditions which have an effect on the infants' gastrointestinal tract/ability to be fed and/or growth (e.g. insulin dependent diabetes mellitus)
* Participation in another clinical intervention study
Minimum Eligible Age

0 Days

Maximum Eligible Age

25 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Waldkrankenhaus Protestant Hospital, Spandau

OTHER

Sponsor Role collaborator

Biofortis, Merieux NutriSciences

INDUSTRY

Sponsor Role collaborator

HungaroTrial

UNKNOWN

Sponsor Role collaborator

HiPP GmbH & Co. Vertrieb KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frank Jochum, PD Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Evangelisches Waldkrankenhaus Spandau, Berlin, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Evangelisches Waldkrankenhaus Spandau

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

508917-2

Identifier Type: -

Identifier Source: org_study_id